However, we investigated whether we would be able to target other concurrent genetic mutations or develop novel strategies to treat CCNE1 amplified cancer cells via synthetic lethal interaction other therapeutics, such as Wee1 kinase or CDK2 kinase inhibition28–30. The gene discussed is CCNE1; the disease is cancer.